Bharat Biotech starts Phase III trials for COVAXIN.Bharat Biotech’s Phase-3 trials will involve 26,000 volunters from 25 centres in India.It’s the largest clinical trial that will be conducted in India .The volunteers will receive two intramuscular injections in a gap of 28 days.
According to Sushitra Ella , Joint Managing Director of Bharat Biotech “The development and clinical evaluation of COVAXIN™ marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. COVAXIN™ has garnered interest from several countries worldwide for supplies and introduction.”
The 25 centers where phase – 3trials will be conducted are as follows
- Bhubaneswar IMS SUM hospital
- New Delhi Guru Tej Bahadur Hospital
- Mumbai Grant Government Medical College and Sir J.J. Group of Hospitals
- Guntur Guntur Medical College
- Bhopal Gandhi Medical College
- Ahmedabad Gmers Medical College and Civil Hospital
- Uttar Pradesh Aligarh Muslim University
- Hyderabad Nizams Institute of Medical Sciences
- Rohtak Pandit Bhagwat Dayal Sharma University of Health Sciences
- Goa Redkar Hospital and Research Centre
- Guwahati institute of medical sciences
- Faridabad ESIC hospital
- New Delhi AIIMS
- Mumbai Lokmanya Tilak Municipal General Hospital And Medical College (Sion Hospital)
- Nagpur Rahate hospital
- Patna AIIMS
- Pondicherry MG Medical College, Sri Balaji Vidyapeeth
- Bangalore Vydehi institute of medical sciences
- Vizag King Gorge Hospital
- Bhopal People’s University
- Kolkata ICMR-National Institute of Cholera and Enteric Diseases
- Chennai Directorate of Public Health and Preventive Medicine, Teynampet
